ECSP088343A - Nuevos derivados imidazopiridina - Google Patents
Nuevos derivados imidazopiridinaInfo
- Publication number
- ECSP088343A ECSP088343A EC2008008343A ECSP088343A ECSP088343A EC SP088343 A ECSP088343 A EC SP088343A EC 2008008343 A EC2008008343 A EC 2008008343A EC SP088343 A ECSP088343 A EC SP088343A EC SP088343 A ECSP088343 A EC SP088343A
- Authority
- EC
- Ecuador
- Prior art keywords
- diseases
- imidazopiridine
- derivatives
- new
- adenosine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502433A ES2274712B1 (es) | 2005-10-06 | 2005-10-06 | Nuevos derivados imidazopiridina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088343A true ECSP088343A (es) | 2008-05-30 |
Family
ID=36295447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008343A ECSP088343A (es) | 2005-10-06 | 2008-04-03 | Nuevos derivados imidazopiridina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7855202B2 (https=) |
| EP (1) | EP1931666A1 (https=) |
| JP (1) | JP2009510152A (https=) |
| KR (1) | KR20080050475A (https=) |
| CN (1) | CN101326181A (https=) |
| AR (1) | AR055676A1 (https=) |
| AU (1) | AU2006299028A1 (https=) |
| CA (1) | CA2624879A1 (https=) |
| EC (1) | ECSP088343A (https=) |
| ES (1) | ES2274712B1 (https=) |
| IL (1) | IL190336A0 (https=) |
| NO (1) | NO20082121L (https=) |
| PE (1) | PE20070706A1 (https=) |
| RU (1) | RU2008117329A (https=) |
| TW (1) | TW200800985A (https=) |
| UY (1) | UY29836A1 (https=) |
| WO (1) | WO2007039297A1 (https=) |
| ZA (1) | ZA200802588B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| ES2303776B1 (es) * | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| CA2684105C (en) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
| AU2008343813B2 (en) * | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| PT2294066E (pt) * | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| WO2010133534A1 (en) * | 2009-05-19 | 2010-11-25 | Cellzome Limited | Bicyclic amino substituted compounds as pi3k inhibitors |
| EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
| US20120003329A1 (en) | 2010-06-30 | 2012-01-05 | Gilead Sciences, Inc. | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension |
| WO2012033149A1 (ja) * | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ampk活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| AR085942A1 (es) | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
| CA2836487A1 (en) * | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| WO2013063221A1 (en) | 2011-10-25 | 2013-05-02 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
| EA201400990A1 (ru) | 2012-04-06 | 2015-01-30 | Пфайзер Инк. | Ингибиторы диацилглицеринацилтрансферазы 2 |
| EP2861596B1 (en) * | 2012-06-19 | 2019-03-20 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| WO2014145852A2 (en) * | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| CN106537128B (zh) | 2014-06-09 | 2021-06-18 | 生物统计股份有限公司 | 用于测量分析物的低成本测试条和方法 |
| SMT202300362T1 (it) | 2014-09-12 | 2023-11-13 | Biohaven Therapeutics Ltd | Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7 |
| ES2580702B1 (es) * | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| CN114859028A (zh) | 2016-07-19 | 2022-08-05 | 生物统计股份有限公司 | 使用批量可校准测试条测量分析物的方法和系统 |
| EP3562306B1 (en) | 2016-12-29 | 2025-02-26 | Ji Xing Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
| JP7227157B2 (ja) | 2016-12-29 | 2023-02-21 | フェーズバイオ ファーマシューティカルズ,インコーポレイテッド | 金属酵素阻害剤化合物 |
| JP6836693B2 (ja) | 2017-09-28 | 2021-03-03 | シーストーン・ファーマスーティカルズ・(スージョウ)・カンパニー・リミテッドCstone Pharmaceuticals (Suzhou) Co., Ltd. | A2a受容体アンタゴニストとしての縮合環誘導体 |
| PT3792260T (pt) * | 2018-05-08 | 2024-10-02 | Nippon Shinyaku Co Ltd | Compostos de azabenzimidazol e produtos farmacêuticos |
| JP2022516969A (ja) | 2019-01-08 | 2022-03-03 | フェーズバイオ ファーマシューティカルズ,インコーポレイテッド | 金属酵素阻害剤化合物 |
| MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
| CA3161582A1 (en) | 2019-11-13 | 2021-05-20 | Nippon Shinyaku Co., Ltd. | Azabenzimidazole compound and medicine |
| BR112022008457A2 (pt) * | 2019-11-13 | 2022-07-26 | Nippon Shinyaku Co Ltd | Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9309573D0 (en) * | 1993-05-10 | 1993-06-23 | Merck Sharp & Dohme | Therapeutic agents |
| KR0151816B1 (ko) * | 1994-02-08 | 1998-10-15 | 강박광 | 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법 |
| US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
| US6096748A (en) | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
| TW520362B (en) | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
| IL136711A0 (en) | 1997-12-19 | 2001-06-14 | Amgen Inc | Substituted pyridine and pyridazine compounds and their pharmaceutical use |
| WO1999065897A1 (en) | 1998-06-19 | 1999-12-23 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| US6841549B1 (en) * | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| DE60001969T2 (de) | 1999-08-31 | 2004-02-05 | Vanderbilt University, Nashville | Selektive antagonisten von a2b adenosinrezeptoren |
| EP1255550A2 (en) | 2000-02-17 | 2002-11-13 | Cv Therapeutics, Inc. | Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| WO2001062233A2 (en) | 2000-02-25 | 2001-08-30 | F. Hoffmann La Roche Ag | Adenosine receptor modulators |
| AU5260601A (en) | 2000-04-26 | 2001-11-07 | Eisai Co Ltd | Medicinal compositions promoting bowel movement |
| CN1446202A (zh) | 2000-08-11 | 2003-10-01 | 卫材株式会社 | 2-氨基吡啶化合物及其作为药物的用途 |
| AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1360286A2 (en) | 2000-09-19 | 2003-11-12 | Chiron Corporation | Characterization of the gsk-3beta protein and methods of use thereof |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| DK1401837T3 (da) * | 2001-06-29 | 2005-11-07 | Cv Therapeutics Inc | Purinderivater som A2B-adenosinreceptorantagonister |
| TWI330183B (https=) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| ATE520694T1 (de) | 2001-11-09 | 2011-09-15 | Gilead Palo Alto Inc | A2b-adenosinrezeptorantagonisten |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| WO2003057689A1 (en) | 2002-01-02 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| WO2003063800A2 (en) | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
| EP1513848A4 (en) | 2002-06-12 | 2005-11-09 | Biogen Idec Inc | METHOD FOR TREATING ISCHEMIA REPERFUSION INJURIES WITH ADENOSINE RECEPTOR ANTAGONISTS |
| WO2004022540A2 (en) | 2002-09-06 | 2004-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Pyridazinone and pyridone derivatives as adenosine antagonists |
| AU2003282726B2 (en) | 2002-10-03 | 2010-10-07 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
| US7468376B2 (en) | 2003-02-27 | 2008-12-23 | Palau Pharma, S.A. | Pyrazolopyridine derivates |
| CA2524778C (en) | 2003-05-06 | 2013-01-29 | Cv Therapeutics, Inc. | Xanthine derivatives as a2b adenosine receptor antagonists |
| KR101222364B1 (ko) | 2003-08-25 | 2013-01-15 | 트로비스 파마슈티칼스 엘엘씨 | 치환된 8-헤테로아릴 크산틴 |
| ES2229928B1 (es) * | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
| GB0323138D0 (en) | 2003-10-03 | 2003-11-05 | Chang Lisa C W | Pyrimidines substituted in the 2,4,6 positions and their different uses |
| CA2543644A1 (en) | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| US7449473B2 (en) | 2003-10-31 | 2008-11-11 | Cv Therapeutics, Inc. | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists |
| GB0401336D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| ES2241496B1 (es) * | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2303776B1 (es) | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
-
2005
- 2005-10-06 ES ES200502433A patent/ES2274712B1/es not_active Expired - Fee Related
-
2006
- 2006-10-03 UY UY29836A patent/UY29836A1/es unknown
- 2006-10-04 PE PE2006001205A patent/PE20070706A1/es not_active Application Discontinuation
- 2006-10-05 KR KR1020087008297A patent/KR20080050475A/ko not_active Withdrawn
- 2006-10-05 AU AU2006299028A patent/AU2006299028A1/en not_active Abandoned
- 2006-10-05 WO PCT/EP2006/009620 patent/WO2007039297A1/en not_active Ceased
- 2006-10-05 CA CA002624879A patent/CA2624879A1/en not_active Abandoned
- 2006-10-05 AR ARP060104379A patent/AR055676A1/es unknown
- 2006-10-05 RU RU2008117329/04A patent/RU2008117329A/ru not_active Application Discontinuation
- 2006-10-05 JP JP2008533934A patent/JP2009510152A/ja active Pending
- 2006-10-05 US US12/089,050 patent/US7855202B2/en not_active Expired - Fee Related
- 2006-10-05 EP EP06806042A patent/EP1931666A1/en not_active Withdrawn
- 2006-10-05 CN CNA2006800371946A patent/CN101326181A/zh active Pending
- 2006-10-05 TW TW095137259A patent/TW200800985A/zh unknown
-
2008
- 2008-03-20 IL IL190336A patent/IL190336A0/en unknown
- 2008-03-20 ZA ZA200802588A patent/ZA200802588B/xx unknown
- 2008-04-03 EC EC2008008343A patent/ECSP088343A/es unknown
- 2008-05-06 NO NO20082121A patent/NO20082121L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200800985A (en) | 2008-01-01 |
| JP2009510152A (ja) | 2009-03-12 |
| AR055676A1 (es) | 2007-08-29 |
| NO20082121L (no) | 2008-07-07 |
| KR20080050475A (ko) | 2008-06-05 |
| ES2274712B1 (es) | 2008-03-01 |
| ZA200802588B (en) | 2009-09-30 |
| US7855202B2 (en) | 2010-12-21 |
| CN101326181A (zh) | 2008-12-17 |
| UY29836A1 (es) | 2007-04-30 |
| EP1931666A1 (en) | 2008-06-18 |
| IL190336A0 (en) | 2009-09-22 |
| WO2007039297A1 (en) | 2007-04-12 |
| US20080275038A1 (en) | 2008-11-06 |
| PE20070706A1 (es) | 2007-09-24 |
| ES2274712A1 (es) | 2007-05-16 |
| RU2008117329A (ru) | 2009-11-20 |
| AU2006299028A1 (en) | 2007-04-12 |
| CA2624879A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088343A (es) | Nuevos derivados imidazopiridina | |
| UY29672A1 (es) | Nuevos derivados de pirazina | |
| UY28854A1 (es) | Nuevos derivados de piridina | |
| WO2010103547A3 (en) | Substituted fused pyrimidine compounds | |
| UY29167A1 (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| GT200900289A (es) | Compuestos organicos.- | |
| TNSN08515A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| PH12019501098A1 (en) | Pyrrolopyrimidines as cftr potentiators | |
| WO2006091496A3 (en) | Benzazole potentiators of metabotropic glutamate receptors | |
| CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
| TNSN08339A1 (en) | 2,6 -substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists | |
| ECSP055768A (es) | Derivados de azol-pirimidina condensados | |
| CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| CL2007003819A1 (es) | Compuestos derivados de isoquinolina e isoquinolinona; composicion farmaceutica; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, entre otras enfermedades. | |
| GT201200201A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
| DE602006012671D1 (de) | Nanoteilchenförmige imatinib-mesylat-formulierungen | |
| CR10682A (es) | Compuestos de tiazol pirazolopirimidina | |
| IL190835A0 (en) | Sulfonamide derivatives, their preparation and use | |
| WO2006067224A3 (en) | Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists | |
| JP2019534331A5 (https=) | ||
| WO2010018112A3 (en) | Monoaryl aminotetralines | |
| WO2009053748A3 (en) | Novel crystalline forms | |
| PE20061438A1 (es) | Nuevas formas cristalinas de bromuro de tiotropio | |
| PE20060373A1 (es) | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |